RecruitingPhase 4NCT07611214

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

PRESERVE: A Multi-Center Phase 4 Study of the Efficacy and Safety of LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab at Inducing Rapid Renal Response in Patients With Lupus Nephritis

Sponsor

Aurinia Pharmaceuticals Inc.

Enrollment

150 participants

Start Date

Apr 22, 2026

Study Type

INTERVENTIONAL

Conditions

Lupus Nephritis

Summary

The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called LUPKYNIS, a biological treatment called belimumab, obinutuzumab or anifrolumab, and others for people with lupus nephritis. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLUPKYNIS

voclosporin

BIOLOGICALbelimumab, obinutuzumab or anifrolumab

BENLYSTA (belimumab), GAZYVA (obinutuzumab) or SAPHNELO (anifrolumab)

DRUGmycophenolic acid analog (MPAA)

CELLCEPT (mycophenolate mofetil \[MMF\]) or MYFORTIC (mycophenolic acid \[MPA\])

DRUGcorticosteroid

prednisone (or equivalent)

Locations(27)

Purushotham & Akther Kotha MD, Inc.

La Mesa, California, United States

Valerius Medical Group & Research Center of Greater Long Beach, Inc.

Los Alamitos, California, United States

Western Nephrology & Metabolic Bone Disease, PC

Arvada, Colorado, United States

Swati Shah MD Rheumatology, LLC

Jacksonville, Florida, United States

Vida Clinical Research

Kissimmee, Florida, United States

Life Clinical Trials

Margate, Florida, United States

CTR Oakwater

Orlando, Florida, United States

Parris and Associates Rheumatology

Lawrenceville, Georgia, United States

Accurate Clinical Research, Inc.

Lake Charles, Louisiana, United States

Arthritis and Rheumatism Associates

Rockville, Maryland, United States

Kansas City Physician Partners

Kansas City, Missouri, United States

University of Nevada Las Vegas

Las Vegas, Nevada, United States

Sahni Rheumatology & Therapy

West Long Branch, New Jersey, United States

Buffalo Rheumatology and Medicine, PLLC

Orchard Park, New York, United States

Arthritis and Osteoporosis Consultants of the Carolinas

Charlotte, North Carolina, United States

Joint and Muscle Research Institute

Charlotte, North Carolina, United States

Rheumatic Disease Associates, Ltd.

Willow Grove, Pennsylvania, United States

Dunes Clinical Research

Dakota Dunes, South Dakota, United States

West Tennessee Research Institute

Jackson, Tennessee, United States

Novel Research LLC

Bellaire, Texas, United States

Liberty Research Center

Dallas, Texas, United States

Texas Arthritis Center

El Paso, Texas, United States

Integrative Rheumatology of South Texas

Harlingen, Texas, United States

Northwest Houston Arthritis Center

Houston, Texas, United States

Texas Tech University Health Science Center

Lubbock, Texas, United States

Texas Rheumatology Research Institute, LLC

Plano, Texas, United States

Nephrology Leaders and Associates, PLLC

Van Vleck, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07611214

Related Trials

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

NCT0705380014 locations

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

NCT05268289103 locations

A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

NCT0759839617 locations

Wellness & Workforce Solution for Lupus/Lupus Nephritis

NCT062171071 location

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT0692554214 locations